SABRSeq: A Randomized Phase Ib Trial of SABR Sequencing with Pembrolizumab in Metastatic Non-Small Cell Lung Cancer (NSCLC).

S. Siva, R. McMahon,M. Bressel, C. Dsouza, R. G. Castle, J. DiIulio,R. Jennens,A. Thai,L. Tan, T. Morris, S. J. Dawson,M. Shaw,N. Plumridge,P. Neeson,D. L. Ball,B. Solomon

International journal of radiation oncology, biology, physics（2023）

引用 0|浏览8

暂无评分

摘要

There was no evidence of a concerning safety signal from either SABR before or after start of pembrolizumab. The combination demonstrated activity with promising PFS and OS and is worthy of evaluation in larger randomized trials.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要